Please note that the ANZCTR website will be unavailable from 1pm until 2pm (AEST) on Wednesday 29th May for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00896558




Registration number
NCT00896558
Ethics application status
Date submitted
7/05/2009
Date registered
7/05/2009
Date last updated
21/06/2017

Titles & IDs
Public title
A Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Subjects
Scientific title
A Double-Blind, Parallel, Randomized, Placebo-Controlled, Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Subjects
Secondary ID [1] 0 0
112668
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Infections, Bacterial 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - GSK1322322/placebo
Treatment: Drugs - GSK1322322/placebo and midazolam

Experimental: Cohort A - A single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.

Experimental: Cohort B - Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.

Experimental: Cohort C - Subjects in the probe cohort will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12. All subjects will receive a single dose of midazolam alone on Day -1, and co-administered with the morning dose of GSK1322322/placebo on Day 1 and Day 12.

Experimental: Cohort D - Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.

Experimental: Cohort E - Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.


Treatment: Drugs: GSK1322322/placebo
GSK1322322/placebo escalating doses from 500mg to 1500mg

Treatment: Drugs: GSK1322322/placebo and midazolam
GSK1322322/placebo and 5mg midazolam

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
GSK1322322 safety parameters, adverse events , absolute values and changes over time of clinical lab testing, vital signs, electrocardiogram
Timepoint [1] 0 0
6 weeks
Primary outcome [2] 0 0
GSK1322322 pharmacokinetic parameters following single dose administration on Day 1 and following repeat administration where applicable on Day 7 and Day 12.
Timepoint [2] 0 0
15 days
Secondary outcome [1] 0 0
PK for midazolam with and without GSK1322322
Timepoint [1] 0 0
15 days
Secondary outcome [2] 0 0
Blood PK for GSK1322322
Timepoint [2] 0 0
15 days
Secondary outcome [3] 0 0
Urine PK for GSK1322322
Timepoint [3] 0 0
15 days
Secondary outcome [4] 0 0
GSK1322322 Age Effect on PK Blood and Urine
Timepoint [4] 0 0
15 days

Eligibility
Key inclusion criteria
- The subject is healthy.

- Male or female between 18 and 65 years of age inclusive, at the time of signing the
informed consent (except for elderly cohort-Part B, see #8 below)..

- A female is eligible to enter and participate in this study if she is of
non-childbearing potential

- Male subjects must agree to use one of the contraception methods in the protocol

- Body weight greater than or equal to 50 kg and body mass index between 18.5-29.9 kg/m2
inclusive

- Capable of giving written informed consent

- QTcB less than 450 msec; or QTc less than 480 msec in subjects with Bundle Branch
Block on Screening ECG

- Part B/Cohort E Elderly cohort: The subject is greater than 65 years of age.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- The subject has a positive pre-study drug/alcohol screen.

- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
result within 3 months of screening.

- A positive test for HIV antibody.

- History of regular alcohol consumption within 6 months of the study defined in the
protocol

- The subject has participated in a clinical trial and has received an investigational
product within the following time period prior to the first dosing day in the current
study: 30 days, 5 half-lives or twice the duration of the biological effect of the
investigational product (whichever is longer).

- Exposure to more than four new chemical entities within 12 months prior to the first
dosing day.

- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
supplements (including St John's Wort) within 7 days (or 14 days if the drug is a
potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first
dose of study medication, unless in the opinion of the Investigator and GSK Medical
Monitor the medication will not interfere with the study procedures or compromise
subject safety.

- History of sensitivity to any of the study medications, or components thereof or a
history of drug or other allergy that, in the opinion of the investigator or GSK
Medical Monitor, contraindicates their participation.

- Where participation in the study would result in donation of blood or blood products
in excess of 500 mL within a 56 day period.

- Pregnant females as determined by positive human chorionic gonadotropin test at
screening or prior to dosing.

- Lactating females.

- Subjects who have asthma or a history of asthma within the past 6 months.

- History of smoking or history of regular use of tobacco- or nicotine-containing
products within 3 months prior to screening.

- Consumption of red wine, seville oranges, grapefruit or grapefruit juice, pummelos,
satsuma, ugli, tangerine, and tangelo, exotic citrus fruits, grapefruit hybrids or
fruit juices from 7 days prior to the first dose of study medication.

- For probe cohort in Part A: any condition or symptom contraindicated for
administration of midazolam including acute narrow-angle or open-angle glaucoma.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
GSK Investigational Site - Randwick
Recruitment postcode(s) [1] 0 0
2031 - Randwick

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will be the first repeat dose administration of GSK1322322 to investigate safety,
tolerability, and pharmacokinetics in healthy subjects as well as elderly volunteer subjects.
The study will also include a P450 probe drug (midazolam) to evaluate the effect of
GSK1322322 to inhibit or induce CYP3A4 substrates.
Trial website
https://clinicaltrials.gov/show/NCT00896558
Trial related presentations / publications
Naderer OJ, Dumont E, Zhu J, Kurtinecz M, Jones LS. Safety, tolerability and pharmacokinetics of repeat dosing of the antibiotic GSK1322322, a peptide deformylase inhibitor: a randomized placebo-controlled study. J Antimicrob Chemother. 2013 Aug;68(8):1901-9. doi: 10.1093/jac/dkt097. Epub 2013 Apr 3.
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications